Cadrenal Therapeutics (CVKD) AGM 2026 summary

Opening remarks and agenda

• Meeting called to order by the chairperson, with board members, management, and external counsel present virtually.

• The meeting was held via webcast, and a quorum was confirmed for conducting business.

• Five agenda items were outlined, with voting instructions and Q&A procedures explained.

Board and executive committee updates

• The board's structure was described, with three classes of directors and a nomination for a Class I director for a three-year term.

Shareholder proposals

• Election of a Class I director for a three-year term was proposed.

• Ratification of the independent registered public accounting firm for fiscal year 2026 was proposed.

• Amendment to the 2022 Successor Equity Incentive Plan to increase available shares to 1 million was proposed.

• Approval for issuance of up to 960,000 shares upon exercise of Series C-1 warrants under NASDAQ rules was proposed.

• Approval for potential adjournment of the meeting to solicit further votes if needed was proposed.